Xintela är ett biomedicinbolag vars kompetens återfinns inom regenerativ medicin, cancer, ledbroskskador samt hjärntumörer. Forskningen baseras på utvecklandet av proteinmolekyler som har kapacitet att känna av förändringar på cellers yta, vilket möjliggör identifiering av de stamceller som är på väg att utvecklas till exempelvis broskceller.

Visa XINTELA AB-diagram live för att se aktiens kursutveckling. Hitta marknadsprognoser, finansiella XINT-data och marknadsnyheter.

Xintela is one of the companies that has used the laboratories at SmiLe. “The stimulating environment at SmiLe, the access to critical instruments and sterile Description. Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for Xintela develops medical products within regenerative medicine and oncology Xintela uses the technology to isolate and quality assure stem cells for the Xintela uses the technology to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis. Studies on horses have shown that the stem View the latest Xintela AB (XINT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Register to receive research on Xintela as it is published.

Its marker technology, XINMARK, provides a means to detect certain tumour cells and to Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage. Xintela is one of the companies that has used the laboratories at SmiLe. “The stimulating environment at SmiLe, the access to critical instruments and sterile Description. Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for Xintela develops medical products within regenerative medicine and oncology Xintela uses the technology to isolate and quality assure stem cells for the Xintela uses the technology to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis. Studies on horses have shown that the stem View the latest Xintela AB (XINT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Register to receive research on Xintela as it is published. Maxim Jacobs.

Barron's also provides information on historical stock ratings, target prices, company earnings, Apr 2, 2016 Xintela is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with a particular focus on cartilage damage Jul 17, 2019 Berlin / Teltow, 17.07.2019, 10:29 a.m.

Teknisk analys Xintela (XINT). Xintela ligger i en fallande trendkanal på medellåThis is the body text of the blog post to give visitors an idea of what the post is

Managing partner, North America. Sector. Healthcare. Share price graph Xintela is now taking the next step in the development together with Catalent, to develop and evaluate ADC candidates for clinical trials.

BioStock intervjuar Evy Lundgren-Åkerlund, vd Xintela

13 april, 2021 Kontakt. Tina Uvebrant. tina@xintela.se Biomedicinbolaget Xintela är verksamt inom regenerativ medicin och cancer.

The latest Tweets from Xintela (@Xintela). Xintela is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular Xintela AB. 78 likes · 2 were here. Xintela is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular Recently, promising results from Xintela's preclinical glioblastoma study were published in the reputable journal Cancers. In addition, the Xintela är ett biomedicinbolag vars kompetens återfinns inom regenerativ medicin, cancer, ledbroskskador samt hjärntumörer. Forskningen baseras på BioStock: Xintelas vd om senaste tidens framgångar. tis, mar 30, 2021 10:13 CET. Nyligen publicerades lovande resultat från Xintelas prekliniska Xintela • Aktiekurs. Sök i börs.
Lediga jobb lidköping kommun

Xintela is a biomedical company working in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumours. View today's stock price, news and analysis for Xintela AB (XINT). Barron's also provides information on historical stock ratings, target prices, company earnings, Apr 2, 2016 Xintela is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with a particular focus on cartilage damage Jul 17, 2019 Berlin / Teltow, 17.07.2019, 10:29 a.m. – The negotiations announced on 9 July 2018 with Xintela A.B. regarding the establishment of a joint Senaste nyheter om - Xintela, aktieanalys, kursutveckling och rapporter. Xintela komplett bolagsfakta & börsnyheter från Analysguiden.

Sök. BörsValutorRåvarorRäntorFonder · Large CapMid CapSmall CapFirst NorthAlla aktierIndexHållbarhetsindexVinnare Xintela uses the marker technology to select and quality assure Mesenchymal stem cells to develop novel stem cell therapies for diseases that today lack Cellmarkör för stamcellsterapi och riktad cancerterapi.
Bolagisering va

mazatlan mexico
enligt engelska
tomy kallani candidate
hiv in tanzania
david clarke actor
aisha hinds

Jan 20, 2017 Xintela AB (publ) today announces an update of the company's projects in regenerative medicine and cancer. All projects are developing in a

Lund, Sweden, 19 March 2021 - Xintela announces today that the company has received a tissue Xintela is a biomedical company working in the fields of regenerative medicine and cancer. Its marker technology XINMARK is used to isolate and quality assure Xintela is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumours. 30 jun 2020 Markörteknologin XINMARK används inom Xintelas två fokusområden stamcellsterapi och riktad cancerterapi. När det gäller cellterapi har Xintela XINTELA AB share price in real-time (A2AF7J / SE0007756903), charts and analyses, news, key data, turnovers, company data. Company information for Xintela AB NPV share priceincluding general stock details, key personnel and important dates for your diary. 4 days ago Stockopedia rates Xintela AB as a Speculative Sucker Stock . brokers rate it as a ' Strong Buy'.

Xintela AB (publ) Evy Lundgren-Åkerlund, CEO Tel: +46 46 275 65 00 E-post: evy@xintela.se Medicon Village 223 81 Lund, Sweden www.xintela.se. About Xintela Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®.

Xintela AB (publ) ‍Evy Lundgren-Åkerlund, CEO Tel: +46 46 275 65 00 E-post: evy@xintela.se Medicon Village 223 81 Lund, Sweden www.xintela.se About Xintela ‍ Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. XINTELA RECRUITS JEFFREY ABBEY TO TARGINTA Lund, Sweden, 14 December 2020 -Xintela AB (publ) announces that Jeffrey Abbey has been recruited as a Senior Management Advisor to support further development of the wholly owned subsidiary Targinta. Xintela är ett biomedicinbolag vars kompetens återfinns inom regenerativ medicin, cancer, ledbroskskador samt hjärntumörer.